Precigen, Inc.
PGENHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePrecigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune. At a $1.76B market cap, Precigen, Inc. ranks as a small-cap company within healthcare. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Market Cap
$1.76B
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-22.50
EPS (TTM)
$-1.21
EPS (Fwd)
$-0.22
ROE
-1145.4%
ROA
-42.1%
Cash
$56.2M
Total Debt
$98.3M
Free CF
-$90.1M
52W Change
181.3%
Annual Financials
Cash vs Debt
The company holds $56.2M in cash, though total debt stands at $98.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$90.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -1145.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $26.9M (2022) to $9.7M (2025), a 64% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PGEN.